<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We examined whether TFPI2 methylation can be used as a molecular marker for <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> by detecting TFPI2 methylation in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients' sera by using quantitative methylation-specific polymerase chain reaction (qMSP) </plain></SENT>
<SENT sid="1" pm="."><plain>The qMSP analysis showed that 39 of 215 (18%) patients exhibited TFPI2 methylation in their serum DNA, suggesting that TFPI2 methylation frequently existed in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients' sera </plain></SENT>
<SENT sid="2" pm="."><plain>After completion of qMSP analysis, clinicopathological data were correlated with molecular data </plain></SENT>
<SENT sid="3" pm="."><plain>TFPI2 methylation was significant in the sera of patients with large (p = 0.0022), poorly differentiated <z:mp ids='MP_0002038'>carcinoma</z:mp> (p = 0.0164), deep invasion (p = 0.0002), lymph node <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> (p = 0.0147), or distant <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> (p &lt; 0.0001) </plain></SENT>
<SENT sid="4" pm="."><plain>Moreover, TFPI2 methylation was observed more frequently according to the progression of TNM stage, suggesting that serum TFPI2 methylation could be detected more easily in patients with advanced <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>We also examined whether serum TFPI2 methylation would be useful in the detection of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, compared to the conventional <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> markers </plain></SENT>
<SENT sid="6" pm="."><plain>Detection rates of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> using the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> markers TFPI2 methylation, CEA and CA19-9, in the serum were 18%, 33%, and 17%, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>In cases where we combined <z:hpo ids='HP_0000001'>all</z:hpo> three markers, the detection rate was 42% </plain></SENT>
<SENT sid="8" pm="."><plain>High sensitivity of qMSP enables detection of smaller amounts of serum <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> DNA </plain></SENT>
<SENT sid="9" pm="."><plain>In principle, the methylation status of a <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e> is not required in advance to detect circulating <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> DNA, suggesting the potential of qMSP as a <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> screening method </plain></SENT>
</text></document>